Exact Mass: 389.19822680000004
Exact Mass Matches: 389.19822680000004
Found 309 metabolites which its exact mass value is equals to given mass value 389.19822680000004
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Cilazprilat
C20H27N3O5 (389.19506120000005)
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Alfuzosin
Alfuzosin is only found in individuals that have used or taken this drug. It is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. [Wikipedia]Alfuzosin is a non-subtype specific alpha(1)-adrenergic blocking agent that exhibits selectivity for alpha(1)-adrenergic receptors in the lower urinary tract. Inhibition of these adrenoreceptors leads to the relaxation of smooth muscle in the bladder neck and prostate, resulting in the improvement in urine flow and a reduction in symptoms in benign prostate hyperplasia. Alfuzosin also inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. G - Genito urinary system and sex hormones > G04 - Urologicals > G04C - Drugs used in benign prostatic hypertrophy > G04CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D000089162 - Genitourinary Agents > D064804 - Urological Agents Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH)[1][2].
alfuzosin
G - Genito urinary system and sex hormones > G04 - Urologicals > G04C - Drugs used in benign prostatic hypertrophy > G04CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D000089162 - Genitourinary Agents > D064804 - Urological Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 3350 Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH)[1][2].
Ala Ala Gln Thr
Ala Ala Thr Gln
Ala Asp Gly Lys
Ala Asp Lys Gly
Ala Gly Asp Lys
Ala Gly Lys Asp
Ala Gly Arg Ser
Ala Gly Ser Arg
Ala Lys Asp Gly
Ala Lys Gly Asp
Ala Asn Ser Val
Ala Asn Val Ser
Ala Gln Ala Thr
Ala Gln Thr Ala
Ala Arg Gly Ser
Ala Arg Ser Gly
Ala Ser Gly Arg
Ala Ser Asn Val
Ala Ser Arg Gly
Ala Ser Val Asn
Ala Thr Ala Gln
Ala Thr Gln Ala
Ala Val Asn Ser
Ala Val Ser Asn
Asp Ala Gly Lys
Asp Ala Lys Gly
Asp Gly Ala Lys
Asp Gly Lys Ala
Asp Lys Ala Gly
Asp Lys Gly Ala
Glu Gly Gly Lys
Glu Gly Lys Gly
Glu Lys Gly Gly
Gly Ala Asp Lys
Gly Ala Lys Asp
Gly Ala Arg Ser
Gly Ala Ser Arg
Gly Asp Ala Lys
Gly Asp Lys Ala
Gly Glu Gly Lys
Gly Glu Lys Gly
Gly Gly Glu Lys
Gly Gly Arg Thr
Gly Gly Thr Arg
Gly Ile Asn Ser
Gly Ile Ser Asn
Gly Lys Ala Asp
Gly Lys Asp Ala
Gly Lys Glu Gly
Gly Leu Asn Ser
Gly Leu Ser Asn
Gly Asn Ile Ser
Gly Asn Leu Ser
Gly Asn Ser Ile
Gly Asn Ser Leu
Gly Asn Thr Val
Gly Asn Val Thr
Gly Gln Ser Val
Gly Gln Val Ser
Gly Arg Ala Ser
Gly Arg Gly Thr
Gly Arg Ser Ala
Gly Arg Thr Gly
Gly Ser Ala Arg
Gly Ser Ile Asn
Gly Ser Leu Asn
Gly Ser Asn Ile
Gly Ser Asn Leu
Gly Ser Gln Val
Gly Ser Arg Ala
Gly Ser Val Gln
Gly Thr Gly Arg
Gly Thr Asn Val
Gly Thr Arg Gly
Gly Thr Val Asn
Gly Val Asn Thr
Gly Val Gln Ser
Gly Val Ser Gln
Gly Val Thr Asn
Ile Gly Asn Ser
Ile Gly Ser Asn
Ile Asn Gly Ser
Ile Asn Ser Gly
Ile Ser Gly Asn
Ile Ser Asn Gly
Lys Ala Asp Gly
Lys Ala Gly Asp
Lys Asp Ala Gly
Lys Asp Gly Ala
Lys Glu Gly Gly
Lys Gly Ala Asp
Lys Gly Asp Ala
Lys Gly Glu Gly
Leu Gly Asn Ser
Leu Gly Ser Asn
Leu Asn Gly Ser
Leu Asn Ser Gly
Leu Ser Gly Asn
Leu Ser Asn Gly
Asn Ala Ser Val
Asn Ala Val Ser
Asn Gly Ile Ser
Asn Gly Leu Ser
Asn Gly Ser Ile
Asn Gly Ser Leu
Asn Gly Thr Val
Asn Gly Val Thr
Asn Ile Gly Ser
Asn Ile Ser Gly
Asn Leu Gly Ser
Asn Leu Ser Gly
Asn Ser Ala Val
Asn Ser Gly Ile
Asn Ser Gly Leu
Asn Ser Ile Gly
Asn Ser Leu Gly
Asn Ser Val Ala
Asn Thr Gly Val
Asn Thr Val Gly
Asn Val Ala Ser
Asn Val Gly Thr
Asn Val Ser Ala
Asn Val Thr Gly
Gln Ala Ala Thr
Gln Ala Thr Ala
Gln Gly Ser Val
Gln Gly Val Ser
Gln Ser Gly Val
Gln Ser Val Gly
Gln Thr Ala Ala
Gln Val Gly Ser
Gln Val Ser Gly
Arg Ala Gly Ser
Arg Ala Ser Gly
Arg Gly Ala Ser
Arg Gly Gly Thr
Arg Gly Ser Ala
Arg Gly Thr Gly
Arg Ser Ala Gly
Arg Ser Gly Ala
Arg Thr Gly Gly
Ser Ala Gly Arg
Ser Ala Asn Val
Ser Ala Arg Gly
Ser Ala Val Asn
Ser Gly Ala Arg
Ser Gly Ile Asn
Ser Gly Leu Asn
Ser Gly Asn Ile
Ser Gly Asn Leu
Ser Gly Gln Val
Ser Gly Arg Ala
Ser Gly Val Gln
Ser Ile Gly Asn
Ser Ile Asn Gly
Ser Leu Gly Asn
Ser Leu Asn Gly
Ser Asn Ala Val
Ser Asn Gly Ile
Ser Asn Gly Leu
Ser Asn Ile Gly
Ser Asn Leu Gly
Ser Asn Val Ala
Ser Gln Gly Val
Ser Gln Val Gly
Ser Arg Ala Gly
Ser Arg Gly Ala
Ser Val Ala Asn
Ser Val Gly Gln
Ser Val Asn Ala
Ser Val Gln Gly
Thr Ala Ala Gln
Thr Ala Gln Ala
Thr Gly Gly Arg
Thr Gly Asn Val
Thr Gly Arg Gly
Thr Gly Val Asn
Thr Asn Gly Val
Thr Asn Val Gly
Thr Gln Ala Ala
Thr Arg Gly Gly
Thr Val Gly Asn
Thr Val Asn Gly
Val Ala Asn Ser
Val Ala Ser Asn
Val Gly Asn Thr
Val Gly Gln Ser
Val Gly Ser Gln
Val Gly Thr Asn
Val Asn Ala Ser
Val Asn Gly Thr
Val Asn Ser Ala
Val Asn Thr Gly
Val Gln Gly Ser
Val Gln Ser Gly
Val Ser Ala Asn
Val Ser Gly Gln
Val Ser Asn Ala
Val Ser Gln Gly
Val Thr Gly Asn
Val Thr Asn Gly
2-({2-[4-(1H-Indazol-3-yl)-1-piperazinyl]ethyl}amino)-4(3H)-quina zolinone
(2R)-2-[4-[(4-chlorophenyl)methyl]-5-methyl-1,2,4-triazol-3-yl]-N-pentan-3-ylpyrrolidine-1-carboxamide
C20H28ClN5O (389.19822680000004)
(R)-Methyl 2-(2-((tert-butoxycarbonyl)amino)-2-Methylpropanamido)-3-(1H-indol-3-yl)propanoate
C20H27N3O5 (389.19506120000005)
(R)-2-(2-((TERT-BUTOXYCARBONYL)AMINO)-2-METHYLPROPANAMIDO)-3-(1H-INDOL-3-YL)PROPANOIC ACID
C20H27N3O5 (389.19506120000005)
N-[2-(3-fluorophenyl)-5-phenyl-7-pyrazolo[1,5-a]pyrimidinyl]-N,N-dimethylpropane-1,3-diamine
[(3aR,4S,9bR)-8-(3-fluorophenyl)-1-(pyridin-4-ylmethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-4-yl]methanol
[(3aS,4S,9bS)-8-(3-fluorophenyl)-1-(pyridin-4-ylmethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-4-yl]methanol
[(3aR,4R,9bR)-8-(3-fluorophenyl)-1-(pyridin-4-ylmethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-4-yl]methanol
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide
C20H27N3O5 (389.19506120000005)
4-hydroxy-6,7-dimethoxy-2-oxo-N-[3-(1-piperidinyl)propyl]-1H-quinoline-3-carboxamide
C20H27N3O5 (389.19506120000005)
2-[(2R,4aS,12aS)-8-acetamido-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-ethylacetamide
C20H27N3O5 (389.19506120000005)
2-[(2S,4aS,12aS)-8-acetamido-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-ethylacetamide
C20H27N3O5 (389.19506120000005)
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide
C20H27N3O5 (389.19506120000005)
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide
C20H27N3O5 (389.19506120000005)
2-[(2S,4aR,12aS)-8-acetamido-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-ethylacetamide
C20H27N3O5 (389.19506120000005)
2-[(2R,4aR,12aR)-8-acetamido-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-ethylacetamide
C20H27N3O5 (389.19506120000005)
2-[(2R,4aS,12aR)-8-acetamido-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-ethylacetamide
C20H27N3O5 (389.19506120000005)
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide
C20H27N3O5 (389.19506120000005)
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide
C20H27N3O5 (389.19506120000005)
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide
C20H27N3O5 (389.19506120000005)
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide
C20H27N3O5 (389.19506120000005)
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide
C20H27N3O5 (389.19506120000005)
2-[(2R,4aR,12aS)-8-acetamido-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-ethylacetamide
C20H27N3O5 (389.19506120000005)
2-[(2S,4aS,12aR)-8-acetamido-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-ethylacetamide
C20H27N3O5 (389.19506120000005)
2-[(2S,4aR,12aR)-8-acetamido-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-ethylacetamide
C20H27N3O5 (389.19506120000005)
Cilazaprilat
C20H27N3O5 (389.19506120000005)
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Antihistamine-1
Antihistamine-1 is a H1-antihistamine (Ki=6.9 nM) with acceptable blood-brain barrier penetration and also an inhibitor of CYP2D6 and hERG channel with IC50s of 5.4 and 0.8 μM, respectively.
SIRT-IN-1
SIRT-IN-1 is a potent inhibitor of SIRT1/2/3, with IC50s of 15, 10, 33 μM, respectively.
3-[(2s,5s,8s)-5-benzyl-3,6,9-trihydroxy-8-(2-methylpropyl)-5,8-dihydro-2h-1,4,7-triazonin-2-yl]propanoic acid
C20H27N3O5 (389.19506120000005)
12,13-dihydroxy-14-oxo-7,15-diazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadecan-4-yl 1h-pyrrole-2-carboxylate
C20H27N3O5 (389.19506120000005)
(4r,7r)-4-[(2s)-butan-2-yl]-6-hydroxy-7-isopropyl-4,12-dimethoxy-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one
C20H27N3O5 (389.19506120000005)
(1r,2s,4s,9r,10r,12r,13s)-12,13-dihydroxy-14-oxo-7,15-diazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadecan-4-yl 1h-pyrrole-2-carboxylate
C20H27N3O5 (389.19506120000005)
(1s,2s,4s,9s,10r,12r,13s)-12,13-dihydroxy-14-oxo-7,15-diazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadecan-4-yl 1h-pyrrole-2-carboxylate
C20H27N3O5 (389.19506120000005)
(4s,7r)-4-[(2s)-butan-2-yl]-6-hydroxy-7-isopropyl-4,12-dimethoxy-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one
C20H27N3O5 (389.19506120000005)